Urothelial carcinoma in the prostatic urethra and prostate: Current controversies

Expert Review of Anticancer Therapy

Volumn 7, Issue 3, 2007, Pages 383-390

  Liedberg, Fredrik ^a   Chebil, Gunilla ^b   Månsson, Wiking ^c  

^a Vaxjo County Hospital   (Sweden)

^b HELSINGBORG HOSPITAL   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Classification; Diagnosis; Incidence; Prognosis; Prostate; Prostatic urethra; Treatment; Urethral recurrence; Urothelial carcinoma

Indexed keywords

BCG VACCINE;

BLADDER CANCER; CANCER CLASSIFICATION; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARCINOMA IN SITU; CONSERVATIVE TREATMENT; CYSTECTOMY; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INCIDENCE; PATIENT COUNSELING; PREOPERATIVE CARE; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CARCINOMA; REVIEW; RISK FACTOR; SEXUAL FUNCTION; TRANSURETHRAL RESECTION; URETHRA CARCINOMA; UROGENITAL TRACT CANCER;

BCG VACCINE; CARCINOMA; CARCINOMA IN SITU; CARCINOMA, TRANSITIONAL CELL; CYSTECTOMY; HUMANS; IMPOTENCE; INCIDENCE; MALE; NEOPLASM INVASIVENESS; POSTOPERATIVE COMPLICATIONS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; TRANSURETHRAL RESECTION OF PROSTATE; TREATMENT OUTCOME; URETHRAL NEOPLASMS; URINARY BLADDER NEOPLASMS; URINARY DIVERSION; URINATION DISORDERS; UROTHELIUM;

EID: 33947693415     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.3.383     Document Type: Review

References (43)

1. Ende N, Woods LP, Shelley HS. Carcinomá originating in ducts surrounding the prostatic urethra. Am. J. Clin. Pathol 40, 183-189 (1963).
2. Hall RH, Robinson MC. Transitional cell carcinoma of the prostate. Eur. Urol. Update Series 7(1), 1-7 (1998).
3. Reese JH, Freiha FS, Gelb AB, Lum BL, Torti FM. Transitional cell carcinoma of the prostate in patients undergoing radical cystoprostatectomy. J. Urol. 147(1), 92-95 (1992).
4. Palou J, Baniel J, Klotz L et al. Urothelial Caninoma of the Pmsiate. Health Pubication Ltd, Paris, France 309-334 (2006).
5. Rikken CH, van Helsdingen PJ, Kazzaz BA. Are biopsies from the prostatic urethra useuful in patients with superficial bladder carcinoma? Br. J. Urol. 59(2), 145-147 (1987).
6. Solsona E, Iborra I, Ricos JV et al. Recurrence of superficial bladder tumors in prostatic urethra. Eur. Urol. 19(2), 89-92 (1991).
7. Davis JW, Sheth SI, Doviak MJ, Schellhammer PF. Superficial bladder carcinoma treated with bacillus Calmette-Guerin: progression-free and disease specific survival with minimum 1 0-year followup. J. Urol. 167(2 Pt 1), 494-500; discussion 501 (2002).
8. Herr HW, Donat SM. Prostatic tumor relapse in patients with superficial bladder tumors: 15-yearoutcome. J. Urol. 161(6), 1854-1857(1999).
9. Nixon RG, Chang SS, Lafleur BJ, Smith JJ, Cookson MS. Carcinoma in situ and tumor multifocality predict the risk of prostatic urethral involvement at radical cystectomy in men with transitional cell carcinoma of the bladder. J. Urol. 167(2 Pt 1), 502-505 (2002).
10. Kefer JC, Voelzke BB, Flanigan RC, Wojcik EM, Waters WB, Campbell SC. Risk assessment for occult malignancy in the prostate before radical cystectomy. Urology 66(6), 1251-1255 (2005).
11. Zincke H, Utz DC, Farrow GM. Review of Mayo Clinic experience with carcinoma in situ. Urology 26(Suppl. 4), 39-46 (1985).
12. Revelo MP, Cookson MS, Chang SS, Shook MF, Smith JA Jr, Shappell SB. Incidence and location of prostate and urothelial carcinoma in prostates from cystoprostatectomies: implications for possible apical sparing surgery. J. Urol. 171(2 Pt 1), 646-651 (2004).
13. Sakamoto N, Tsuneyoshi M, Naito S, Kumazawa J. An adequate sampling of the prostate to identify prostatic involvement by urothelial carcinoma in bladder cancer patients. J. Urol. 149(2), 318-321 (1993).
14. Liedberg F, Chebil G, Davidsson T, Malmstrom PU, Sherif A, Mansson W. Transitional cell carcinoma ofthe prostate in cystoprostatectomy specimens. Aktuelle Urol. 34(5), 333-336 (2003).
15. Donat SM, Wei DC, McGuire MS, Herr HW. The efficacy of transurethral biopsy for predicting the long-term clinical impact of prostatic invasive bladder cancer. J. Urol. 165(5), 1580-1584 (2001).
16. Wood DP Jr, Montie JE, Pontes JE, Levin HS. Identification of transitional cell carcinoma of the prostate in bladder cancer patients: a prospective study. J. Urol. 142(1), 83-85 (1989).
17. Njinou Ngninkeu B, Lorge F, Moulin P, Jamart J, Van Cangh PJ. Transitional cell carcinoma involving the prostate: a clinicopathological retrospective study of 76 cases. J. Urol. 169(1), 149-152 (2003).
18. Esrig D, Freeman JA, Elmajian DA et al. Transitional cell carcinoma involving the prostate with a proposed staging classification for stromal invasion. J. Urol. 156(3), 1071-1076 (1996).
19. Pagano F, Bassi P. Ferrante GL et al. Is stage pT4a (D1) reliable in assessing transitional cell carcinoma involvement of the prostate in patients with a concurrent bladder cancer? A necessary distinction for contiguous or noncontiguous involvement. J. Urol. 155(1), 244-247 (1996).
20. Donat SM, Genega EM, Herr HW, Reuter VE. Mechanisms of prostatic stromal invasion in patients with bladder cancer: clinical significance. J. Urol. 165(4), 1117-1120 (2001).
21. Liedberg F, Chebil G, Mansson W. Hematogcnous dissemination of transitional cell carcinoma in the bladder to the prostate. Scand. J. Urol. Nephrol. 37(4), 359-360 (2003).
22. Solsona E, Iborra I, Rubio J, Casanova J, Almenar S. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour. Br. J. Urol. Int. 94(9), 1258-1262 (2004).
23. Wittekind C, Greene FL, Hutter RVP, Henson TE, Sobin LH (Eds). TNM SuppLement: A Commentary on Uniform Use (3rd Edition). Wiley-Liss, Geneva, Switzerland 67-69 (2003).
24. Shen SS, Lerner SP, Muezzinoglu B, Truong LD, Amiel G, Wheeler TM. Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance. Hum. Pathol. 37(6), 726-734 (2006).
25. Hillyard RW Jr, Ladaga L, Schellharnmer PF. Superficial transitional cell carcinoma of the bladder associated with mucosal involvement of the prostatic urethra: results of treatment with intravesical bacillus Calmette-Guerin. J. Urol. 139(2), 290-293 (1988).
26. Bretton PR, Herr HW, Whitmore WF Jr et al. Intravesical bacillus Calmette-Guerin therapy for in situ transitional cell carcinoma involving the prostatic urethra. J. Urol, 141(4), 853-856 (1989).
27. Schellhammer PF, Ladaga LE, Moriarty RP. Intravesical bacillus Calmette-Guerin for the treatment of superficial transitional cell carcinoma of the prostatic urethra in association with carcinoma of the bladder. J. Urol. 153(1), 53-56 (1995).
28. Palou J, Xavier B, Laguna P, Montlleo, M, Vicente J. In situ transitional cell carcinoma involvement of prostatic urethra: bacillus Calmette-Guerin therapy without previous transurethral resection of the prostate. Urology 47(4), 482-484 (1996).
29. Canda AE, Tuzel E, Mungan MU, Yorukoglu K. Kirkali Z. Conservative management of mucosal prostatic urethral involvement in patients with superficial transitional cell carcinoma of the bladder. Eur. Urol. 45(4), 465-469; discussion 469-470(2004).
30. Palou J, López H, Millán F, Oliver A, Salvador J, Vicente J. Effect of intravesical instillations of BCG on total PSA. Preliminary results. Br. J. Urol. Int. 86(Suppl. 3), 254 (2000).
31. Orihuela E, Herr HW, Whitmore WF Jr. Conservative treatment of superficial transitional cell carcinoma of prostatic urethra with intravesical BCG. Urology 34(5), 231-237 (1989).
32. Solsona E, Iborra I, Ricos JV, Monros JL, Casanova JL, Almenar S. The prostate involvement as prognostic factor in patients with superficial bladder tumors. J. Urol. 154(5), 1710-1713 (1995).
33. Vazina A, Dugi D, Shariat SF, Evans J, Link R, Lerner SP. Stage specific lymph node metastasis mapping in radical cystectomy specimens. J. Urol. 171(5), 1830-1834 (2004).
34. Hautmann RE, Stein JP. Neobladder with prostatic capsule and seminal-sparing cystectomy for bladder cancer: a step in the wrong direction. Urol. Clin. North Am. 32(2), 177-185 (2005).
35. Freeman JA, Esrig D, Stein JP, Skinner DG. Management of the patient with bladder cancer. Urethral recurrence. Urol. Clin. North Am. 21(4), 645-651 (1994).
36. Stein JP, Clark P, Miranda G, Cai J, Groshen S, Skinner DG. Urethral tumor recurrence following cystectomy and urinary diversion: clinical and pathological characteristics in 768 male patients. J. Urol. 173(4), 1163-1168 (2005).
37. Freeman JA, Tatter TA, Esrig D et al. Urethral recurrence in patients with orthotopic ileal neobladders: J. Urol. 156(5), 1615-1619 (1996).
38. Lehret T, Herve JM, Barre P et al. Urethral recurrence of transitional cell carcinoma ofthe bladder. Predictive value of preoperative latero-montanal biopsies and urethral frozen sections during prostatocystectomy. Eur. Urol. 33(2), 170-174 (1998).
39. Iselin CE, Robertson CN, Webster GD, Vieweg J, Paulson DE Does prostate transitional cell carcinoma preclude orthotopic bladder reconstruction after radical cystoprostatectomy for bladder cancer? J. Urol. 158(6), 2123-2126 (1997).
40. Kitamura. T, Moriyama N, Shibamoto K et al. Urethrectomy is harmful for preserving potency after radical cystectomy. Urol. Int. 42(5), 375-379 (1987).
41. Tomic R, Sjodin JG. Sexual function in men after radical cystectomy with or without urethrectomy. Scand. J. Urol. Nephrol.L 26(2), 127-129 (1992).
42. Schellhammer PF, Bean MA, Whitmore WF Jr. Prostatic involvement by transitional cell carcinoma: pathogenesis, patterns and prognosis. J. Urol. 118(3), 399-403 (1977).
43. Solsona E, Iborra I, Dumont R, Rubio J, Casanova JL, Almenar S. Risk groups in patients with bladder cancer treated with radical cystectomy: statistical and clinical model improving homogeneity. j. Urol. 174(4 Pt 1), 1226-1230 (2005).